ZBH.SW Zimmer Biomet (SIX) at CHF75.00 24 Feb 2026: volume spike tests resistance

Intraday action shows ZBH.SW stock trading at CHF75.00 on 24 Feb 2026 after a sharp volume spike that pushed the price +6.38% from yesterday’s close. The move places Zimmer Biomet Holdings, Inc. (ZBH.SW) on a near-term technical test against the 50‑day average of CHF78.58 and the stock’s year low of CHF67.50. Fundamentals are mixed: EPS CHF2.80 and PE 24.11, while free cash flow yield is 9.15%. Traders should watch whether the volume spike holds through the close, as it will shape the intraday trend and short-term trade setups.

ZBH.SW stock intraday price and volume signal

Price action shows CHF75.00 with a one‑day gain of +6.38% and an absolute change of CHF4.50. That intraday gain arrived with a reported relative volume of 36.67x against an average volume of 3 shares, signalling concentrated trading interest.

Technical indicators support a short-term tug of war. The RSI is 51.80, CCI 183.33 (overbought), and ADX 93.82 (strong trend), so the volume spike must sustain to confirm a breakout above short-term resistance.

Catalysts, news flow and upcoming events for ZBH.SW stock

There are no company-specific headlines driving the spike on this tape beyond routine market chatter. The most recent market mention appears via a Investing.com report that restates Zimmer Biomet’s business profile.

Key calendar items include the scheduled earnings announcement on 2026-05-04. That date is a likely catalyst for renewed volume and price direction. Sector context: Healthcare peers trade at a higher average PE of 35.08, which frames valuation comparisons.

Fundamentals and valuation snapshot for ZBH.SW stock

Zimmer Biomet (ZBH.SW) trades at PE 24.11 with EPS CHF2.80, market cap approx CHF13.38B, and shares outstanding 198,181,555. Price/book is 1.35 and EV/EBITDA stands near 11.80, suggesting mid‑cycle valuation versus large healthcare peers.

Balance sheet metrics include debt/equity 0.59 and interest coverage 4.16. Free cash flow per share is CHF8.02, producing a free cash flow yield 9.15%, which offsets some valuation concerns.

Meyka AI grade and ZBH.SW stock forecast

Meyka AI rates ZBH.SW with a score out of 100: 77.44 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guarantees and are not financial advice.

Meyka AI’s forecast model projects monthly CHF57.46, quarterly CHF63.20, and yearly CHF57.27. Versus the current CHF75.00, the model implies short‑term downside of -23.54% to the monthly figure, -21.07% to the quarterly level, and -23.64% to the yearly level. Forecasts are model-based projections and not guarantees.

Technicals, price targets and trading scenarios for ZBH.SW stock

Immediate resistance sits near the 50‑day average CHF78.58 and the Keltner upper band at CHF75.29. Support is visible at the day low CHF75.00 and the year low CHF67.50.

Analyst-style price targets for traders: conservative CHF68.00 (downside -9.33%), base CHF80.00 (upside +6.67%), bull CHF95.00 (upside +26.67%). A close above CHF78.58 on sustained volume would strengthen the bullish case.

Risks, opportunities and sector view for ZBH.SW stock

Key risks include prolonged margin pressure—net income fell year-on-year—and a net debt to EBITDA near 3.38, which raises leverage sensitivity. Inventory days are long at 311 days, adding working capital risk.

Opportunities include a strong free cash flow profile and exposure to elective orthopaedic recovery demand. Healthcare sector peers trade richer on PE, which could support multiple expansion if growth returns.

Final Thoughts

Intraday volume on 24 Feb 2026 lifted ZBH.SW stock to CHF75.00, creating a short-term trading test of the 50‑day average CHF78.58. The spike shows fresh interest, but technical confirmation requires sustained volume above the average. Our Meyka AI grade (B+, score 77.44) balances healthy cash flow and reasonable PE against leverage and inventory risks. Meyka AI’s forecast model projects yearly CHF57.27, implying an illustrative downside of -23.64% versus today’s price. Traders should treat the move as an opportunity to set defined risk points: a break and hold above CHF78.58 would favour bullish targets near CHF80.00 and CHF95.00. If volume fades and the stock closes back below CHF75.00, short-term sellers may test CHF68.00. These scenarios combine intraday volume signals and fundamentals to guide active trading and tactical allocation decisions. Meyka AI provides this as AI-powered market analysis and not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.